Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1993 2
1995 1
1996 1
1997 2
1998 5
1999 5
2000 2
2001 5
2003 1
2004 5
2005 3
2006 3
2007 3
2008 2
2009 4
2010 4
2011 13
2012 12
2013 4
2014 9
2015 12
2016 10
2017 10
2018 10
2019 10
2020 12
2021 8
2022 11
2023 10
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: mourey l. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Among authors: mourey l. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Eisenberger M, et al. Among authors: mourey l. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15. J Clin Oncol. 2017. PMID: 28809610 Clinical Trial.
Protein X-ray Crystallography and Drug Discovery.
Maveyraud L, Mourey L. Maveyraud L, et al. Among authors: mourey l. Molecules. 2020 Feb 25;25(5):1030. doi: 10.3390/molecules25051030. Molecules. 2020. PMID: 32106588 Free PMC article. Review.
Microtubule nucleation by γ-tubulin complexes.
Kollman JM, Merdes A, Mourey L, Agard DA. Kollman JM, et al. Among authors: mourey l. Nat Rev Mol Cell Biol. 2011 Oct 12;12(11):709-21. doi: 10.1038/nrm3209. Nat Rev Mol Cell Biol. 2011. PMID: 21993292 Free PMC article. Review.
Perspectives on cancer care in older patients in France.
Hauchecorne M, Pierro M, Brain E, Bringuier M, Soubeyran P, Chakiba C, Mathoulin-Pelissier S, Paillaud E, Geiss R, Besse B, Mourey L, Vincent H, Baldini C. Hauchecorne M, et al. Among authors: mourey l. Ecancermedicalscience. 2020 Sep 15;14:1103. doi: 10.3332/ecancer.2020.1103. eCollection 2020. Ecancermedicalscience. 2020. PMID: 33082853 Free PMC article. Review.
Staphylococcal pore-forming toxins.
Prévost G, Mourey L, Colin DA, Menestrina G. Prévost G, et al. Among authors: mourey l. Curr Top Microbiol Immunol. 2001;257:53-83. doi: 10.1007/978-3-642-56508-3_4. Curr Top Microbiol Immunol. 2001. PMID: 11417122 Review. No abstract available.
Immune checkpoint inhibitor-related acral vasculitis.
Comont T, Sibaud V, Mourey L, Cougoul P, Beyne-Rauzy O. Comont T, et al. Among authors: mourey l. J Immunother Cancer. 2018 Nov 16;6(1):120. doi: 10.1186/s40425-018-0443-6. J Immunother Cancer. 2018. PMID: 30446009 Free PMC article.
170 results